{
  "pmid": "34058104",
  "uid": "34058104",
  "title": "In COVID-19, tocilizumab reduces all-cause mortality at 28 d.",
  "abstract": "Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;3:CD013881. 33734435.",
  "authors": [
    {
      "last_name": "Fernando",
      "fore_name": "Shannon M",
      "initials": "SM",
      "name": "Shannon M Fernando",
      "affiliations": [
        "University of Ottawa, Ottawa, Ontario, Canada (S.M.F.)."
      ]
    },
    {
      "last_name": "Rochwerg",
      "fore_name": "Bram",
      "initials": "B",
      "name": "Bram Rochwerg",
      "affiliations": [
        "McMaster University, Hamilton, Ontario, Canada (B.R.)."
      ]
    }
  ],
  "journal": {
    "title": "Annals of internal medicine",
    "iso_abbreviation": "Ann Intern Med",
    "issn": "1539-3704",
    "issn_type": "Electronic",
    "volume": "174",
    "issue": "6",
    "pub_year": "2021",
    "pub_month": "Jun"
  },
  "start_page": "JC63",
  "pages": "JC63",
  "language": "eng",
  "publication_types": [
    "Journal Article",
    "Comment"
  ],
  "keywords": [
    "Antibodies, Monoclonal, Humanized",
    "Humans",
    "Interleukin-6",
    "SARS-CoV-2",
    "COVID-19 Drug Treatment"
  ],
  "article_ids": {
    "pubmed": "34058104",
    "doi": "10.7326/ACPJ202106150-063"
  },
  "doi": "10.7326/ACPJ202106150-063",
  "dates": {
    "completed": "2021-06-21",
    "revised": "2022-12-07"
  },
  "chemicals": [
    "Antibodies, Monoclonal, Humanized",
    "Interleukin-6",
    "tocilizumab"
  ],
  "grants": [],
  "search_metadata": {
    "search_type": "current_affiliation",
    "retrieved_date": "2025-07-30T14:54:35.092147",
    "pmid": "34058104"
  }
}